1 / 6

SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2)

SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2). Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events or death from any cause HR = 0.89 (0.79-1.00), p=0.05 First events CVD: HR = 0.88 (0.77-1.01), p = 0.07

pules
Download Presentation

SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) • Enalapril/ACEI vs. HCTZ, n = 6,083 • Randomized, open-label (blinded endpoint review) • All CV events or death from any cause • HR = 0.89 (0.79-1.00), p=0.05 • First events • CVD: HR = 0.88 (0.77-1.01), p = 0.07 • CHD: HR = 0.86 (0.70-1.06), p = 0.16 • Stroke: HR = 1.02 (0.78-1.33), p = 0.91 • HF: HR = 0.85 (0.62-1.18), p = 0.33 NEJM 2003;348:583-92

  2. SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2)Results by Gender NEJM 2003;348:583-92

  3. ALLHAT vs. ANBP2Baseline Characteristics * ALLHAT: no washout, ANBP2: after washout

  4. ALLHAT vs. ANBP2Blood Pressure & Endpoints

  5. ALLHAT vs. ANBP-2 • Randomized double-blind vs. PROBE design • ACEI vs. thiazide-type diuretic, n = 24,309 vs. 6,083 • Number of patients with events • CVD: n = 6,455 vs. 823 • CHD: n = 3,956 vs. 368 • Stroke: n = 1,132 vs. 219 • Heart failure: n = 1,482 vs. 147 • Treatment differences consistent across gender subgroup vs. differences noted only in men • SBP slightly lower with diuretic in both trials

  6. CONCLUSIONS – ALLHAT vs. ANBP2 • ALLHAT had 4 times the number of participants, 5-10 times more endpoints, and a double-blinded design • Even so, the upper 95% CI of ANPB2 compatible with ALLHAT point estimates of relative risk: • Coronary events • Stroke • Heart failure • ALLHAT - no ACE advantage for any outcomes in either men or women, and heart failure outcomes were worse compared to the diuretic. • While the aggregate analyses will have to await those planned by the Blood Pressure Lowering Treatment Trialists’ Collaboration, the totality of trial evidence from ALLHAT and other individual trials favors the diuretic.

More Related